Clinical Performance and Reproducibility of the Accelerate PhenoTest™ Blood Culture (BC) Kit With New Antibiotic Wave I Updates

Bacteremia Clinical Trial

Official title:

Clinical Performance and Reproducibility of the Accelerate PhenoTest™ BC Kit Using the Accelerate Pheno™ System With New Antibiotic Wave I Updates for Antimicrobial Susceptibility Testing of Positive Blood Culture Specimens

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04295915
• Other study ID #: CP000026
• Status: Completed
• Start date: March 11, 2020
• Est. completion date: April 19, 2022

Study information

• Verified date: April 2022
• Source: Accelerate Diagnostics, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This is a performance and reproducibility study to validate new or updated antimicrobials on the Accelerate PhenoTest™ BC kit. The data from this study will be used to support the submission to the FDA for clearance in the US and for global registrations of the device intended for in vitro diagnostic use.

Description:

This clinical study entitled "Clinical Performance and Reproducibility of the Accelerate PhenoTest™ BC Kit Using the Accelerate Pheno™ System with New Antibiotic Wave I Updates for Antimicrobial Susceptibility Testing of Positive Blood Culture Specimens" is designed to demonstrate the clinical performance and reproducibility of the new or updated antimicrobials on the Accelerate PhenoTest™ BC kit, which was previously FDA-cleared in February 2017.

Clinical performance and reproducibility evaluations will be conducted at a minimum of three sites to determine the clinical performance of the new or updated antimicrobials from a combination of fresh (de-identified, remnant specimens) and contrived positive blood culture samples, to include at least 375 total specimens.

The study sites selected will have expertise in blood culture diagnostics and will be able to conduct the study in accordance with this protocol and Good Clinical Practices (GCP). Additionally, prior to study initiation, each site will have approval from the local Institutional Review Board (IRB).

It is anticipated that the data from this study will be used to support the submission to the FDA for clearance in the US and for global registrations of the device intended for in vitro diagnostic use.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 731
• Est. completion date: April 19, 2022
• Est. primary completion date: December 2, 2021
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Blood culture positivity is = 8 hours prior to initiation of testing with the Accelerate Pheno™ system

• Positive blood culture sample containing gram-negative rods according to Gram stain results

• For fresh specimens, de-identified, remnant positive blood culture specimens from patients for which Standard of Care (SOC) testing has been initiated and the remaining samples would otherwise be discarded

• A minimum sample volume of 2.0 mL

• Seeded blood culture specimens derived from archived bacterial

Exclusion Criteria:

• Blood culture positivity is > 8 hours prior to initiation of testing with the Accelerate Pheno™ system

• Insufficient (less than 2.0 mL) remnant sample volume

• From a patient that has already been enrolled in the study

• Fresh samples from Mycobacterial-type blood culture media (BACTEC™ Myco/F Lytic, BacT/ALERT® MP Bottle, VersaTREK® Myco) or charcoal-containing media

• Seeded specimens that appear mixed (by Gram stain or purity plating) after bottle culture positivity

Related Conditions & MeSH terms

• Bacteremia

Intervention

Device:
• Specimens that meet inclusion criteria
Specimens that have been de-identified and considered remnant by the laboratory (fresh specimens) or were contrived by the laboratory (using bacterial isolates with no identifying information) can be enrolled into the study.

Locations

Country	Name	City	State
United States	Penn State-Hershey Medical Center	Hershey	Pennsylvania
United States	Quest/med fusion	Lewisville	Texas
United States	Accelerate Diagnostics	Tucson	Arizona

Sponsors (1)

Lead Sponsor	Collaborator
Accelerate Diagnostics, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Essential and categorical agreement with Clinical and Laboratory Standards Institute (CLSI) broth microdilution reference method		Approximately 4 months
Secondary	Essential agreement of MICs compared to the modal MIC values obtained for intra- and inter-laboratory results		Approximately 2 months